| SCHEDULE OF GRANTED AND ISSUED STOCK AWARDS |
Issuances
under the 2021 Stock Plan in the period January 1 and March 31, 2025
SCHEDULE OF GRANTED AND ISSUED STOCK AWARDS
| Date |
|
|
#
Shares | |
|
| Amount | | |
| Price/Share | |
Type | |
Notice | |
| 1/01/2025 |
|
|
| 5,520,101 | |
|
$ | 481,057 | | |
$ | 0.087 | |
| |
| |
| 1/06/2025 |
* |
|
| 634,921 | |
|
| 43,045 | | |
| 0.067 | |
stipend | |
affiliate | |
| 1/06/2025 |
|
|
| 164,731 | |
|
| 11,037 | | |
| 0.067 | |
stipend | |
| |
| 1/06/2025 |
* |
|
| 1,315,780 | |
|
| 88,031 | | |
| 0.067 | |
bonus | |
affiliate | |
| 1/06/2025 |
|
|
| 1,184,220 | |
|
| 78,914 | | |
| 0.067 | |
bonus | |
| |
| 3/31/2025 |
|
|
| 8,819,753 | |
|
$ | 702,084 | | |
$ | 0.080 | |
| |
| |
There
has been no issuance under the 2021 Stock Plan in the period January 1 and March 31, 2026
| Date | |
#
Shares | | |
Amount | | |
Price/Share | | |
Type | |
Notice |
| 3/31/2026 | |
| 10,062,844 | | |
$ | 809,407 | | |
$ | 0.080 | | |
| |
|
Shares
awarded, but not yet issued, under the 2021 Stock Plan at March 31, 2026:
| Date |
| |
#
Shares | | |
Amount | | |
Price/Share | |
Type | |
Notice | |
| 1/01/2026 |
* | |
| 1,081,875 | | |
$ | 82,006 | | |
$ | 0.076 | |
stipend | |
affiliate | |
| 1/01/2026 |
| |
| 150,250 | | |
| 11,389 | | |
| 0.076 | |
stipend | |
| |
| 1/30/2026 |
*† | |
| 30,000,000 | | |
| 1,278,600 | | |
| 0.043 | |
performance
grant | |
affiliate | |
| 3/31/2026 |
| |
| 254,240 | | |
| 11,415 | | |
| 0.045 | |
stipend | |
| |
| 3/31/2026 |
| |
| 31,486,365 | | |
$ | 1,383,410 | | |
$ | 0.044 | |
| |
| |
| * |
The shares will be issued as shares of Preferred Stock, but are for comparison purposes expressed as Common share
equivalents in this table. |
| † |
The
Board of Directors awarded the CEO 6,000,000
Preferred
Shares, a
1:5 conversion, as a performance grant in recognition for his role in advancing capital funding
initiatives and establishing a distribution agreement for dietary supplements.
|
| (2) |
The Board of Directors awarded the CEO 6,000,000 Preferred Shares, a 1:5 conversion, as a performance grant in recognition for his role in advancing capital funding initiatives and establishing a distribution agreement for dietary supplements.
|
| |
|
| |
The Company claims an exemption from the registration requirements of the Securities Act for the compensatory benefit
plan pursuant to Rule 701 of the Securities Act. |
|